MichelleL.MellionMD
Neurology • Providence, RINeurophysiology
Assistant Professor, Neurology, Brown University Program in Medicine
Dr. Mellion is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Dudley St
Ste 555
Providence, RI 02905Phone+1 401-444-3032Fax+1 401-444-3205
Education & Training
Brown UniversityFellowship, Clinical Neurophysiology, 2005 - 2006- Brown UniversityResidency, Neurology, 2002 - 2005
- Brown UniversityInternship, Internal Medicine, 2001 - 2002
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2001
Certifications & Licensure
RI State Medical License 2005 - 2026
MA State Medical License 2006 - 2025- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Publications & Presentations
PubMed
- 388 citationsSafety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
The Lancet. Neurology. 2017-12-01 - 12 citationsExperimental Alcohol-Related Peripheral Neuropathy: Role of Insulin/IGF ResistanceVan Anh Nguyen, Tran Le, Ming Tong, Michelle Mellion, James M. Gilchrist
Nutrients. 2012-08-17 - 152 citationsA randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F. Howard, Richard J. Barohn, Gary Cutter, Miriam Freimer, Vern C. Juel
Muscle & Nerve. 2013-07-01
Press Mentions
PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentApril 5th, 2022
Phase 1 Results Support Losmapimod as FSHD TreatmentMarch 26th, 2020
Fulcrum Therapeutics Announces Phase 1 Clinical Trial ResultsOctober 4th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
